

**FREMANEZUMAB injection (Ajovy® ▼) for prevention of migraine**

**The Pan Mersey Area Prescribing Committee recommends the prescribing of FREMANEZUMAB (Ajovy® ▼), by specialists only, for prevention of migraine in accordance with NICE TA764.**

**RED**

[NICE technology appraisal \(TA\)764](#) updates and replaces NICE [TA631](#) and recommends fremanezumab as an option for preventing migraine in adults, only if:

- > they have 4 or more migraine days a month
- > at least 3 preventive drug treatments have failed and
- > the company provides it according to the commercial arrangement<sup>(1)</sup>

Treatment should be initiated by a specialist experienced in the diagnosis and treatment of migraine. Prescribing should be retained by the specialist.

Fremanezumab should be stopped after 12 weeks if:

- > in episodic migraine (fewer than 15 headache days a month), the frequency does not reduce by at least 50%<sup>2</sup>
- > in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine), the frequency does not reduce by at least 30%<sup>(1)</sup>

For further information on the prevention of migraine, please refer to the following national and local guidance:

- > NICE Clinical Guideline [CG150] [Headaches in over 12s: diagnosis and management](#), updated December 2021.
- > British Association for the Study of Headache, [National Headache Management System for Adults](#), 2019
- > Pan Mersey Area Prescribing Committee Headache pathway [Headache pathway \(adults\)](#), last updated 30 July 2020.

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because fremanezumab is a further treatment option, and the overall cost of treatment will be similar. The resource impact assumptions made are unchanged for both chronic and episodic migraine.<sup>(2)</sup>

**References**

1. National Institute for Health and Care Excellence. Technology appraisal guidance 764: [Fremazenzumab for preventing migraine](#), 02 February 2022. Accessed 10 February 2022.
2. National Institute for Health and Care Excellence. Technology appraisal guidance 764: Resource impact statement, [Fremazenzumab for preventing migraine](#), 02 February 2022. Accessed 14 March 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.